🇺🇸 FDA
Patent

US 6129914

Bispecific antibody effective to treat B-cell lymphoma and cell line

expired A61KA61K2039/505A61K38/00

Quick answer

US patent 6129914 (Bispecific antibody effective to treat B-cell lymphoma and cell line) held by Protein Design Labs, Inc. expires Mon Oct 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Protein Design Labs, Inc.
Grant date
Tue Oct 10 2000 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2039/505, A61K38/00, A61P, A61P35/00